A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants

被引:27
作者
Hemmati, Philipp G. [1 ]
Terwey, Theis H. [1 ]
le Coutre, Philipp [1 ]
Vuong, Lam G. [1 ]
Massenkeil, Gero [2 ]
Doerken, Bernd [1 ]
Arnold, Renate [1 ]
机构
[1] Charite, Dept Hematol Oncol & Tumorimmunol, Campus Virchow Klinikum, D-13353 Berlin, Germany
[2] Stadt Klinikum Gutersloh, Dept Hematol Oncol & Gastroenterol, Gutersloh, Germany
关键词
allogeneic stem cell transplantation; acute myeloid leukemia; risk score; outcome prediction; reduced-intensity conditioning; 1ST COMPLETE REMISSION; BONE-MARROW-TRANSPLANTATION; COMORBIDITY INDEX; MYELODYSPLASTIC SYNDROME; POSTREMISSION THERAPY; PERFORMANCE STATUS; INTENSITY; DONOR; DISEASE; AML;
D O I
10.1111/j.1600-0609.2011.01580.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The systematic and standardized pretransplant risk assessment represents an important tool to predict the outcome of patients undergoing allogeneic stem cell transplantation (alloSCT). To investigate the capacity of a modified European group for blood and marrow transplantation (mEBMT) risk score to predict the outcome of patients with acute myeloid leukemia (AML) receiving allogeneic stem cell transplants, we retrospectively analyzed 214 patients transplanted at our center between 1995 and 2008. Overall survival (OS) of the whole cohort at 1, 3, and 5 yr was 62%, 48%, and 45%, whereas the cumulative incidence of relapse or non-relapse mortality (NRM) was 26%, 33%, and 33% or 19%, 21%, and 22%. In univariate analysis, a higher mEBMT risk score was associated with an inferior OS ranging from 69% for patients with a score of 0/1 to 26% for patients with a score of 5/6 at 5 yr (P < 0.0001) and steadily increasing hazard ratios for each additional score point. Likewise, a higher mEBMT risk score was associated with an increased incidence of relapse (P = 0.049). Importantly, the prognostic value of the mEBMT risk score in terms of OS and relapse was maintained in multivariate analysis. Taken together, this indicates that a mEBMT risk score may be used to predict the outcome of patients with AML following alloSCT.
引用
收藏
页码:305 / 316
页数:12
相关论文
共 44 条
[1]   A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation [J].
Armand, Philippe ;
Kim, Haesook T. ;
Cutler, Corey S. ;
Ho, Vincent T. ;
Koreth, John ;
Ritz, Jerome ;
Alyea, Edwin P. ;
Antin, Joseph H. ;
Soiffer, Robert J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (01) :28-35
[2]   Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation [J].
Artz, Andrew S. ;
Pollyea, Daniel A. ;
Kocherginsky, Masha ;
Stock, Wendy ;
Rich, Elizabeth ;
Odenike, Olatoyosi ;
Zimmerman, Todd ;
Smith, Sonali ;
Godley, Lucy ;
Thirman, Michael ;
Daugherty, Christopher ;
Extermann, Martine ;
Larson, Richard ;
van Besien, Koen .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (09) :954-964
[3]   Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia [J].
Blaise, Didier ;
Vey, Norbert ;
Faucher, Catherine ;
Mohty, Mohamad .
HAEMATOLOGICA, 2007, 92 (04) :533-541
[4]   Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia [J].
Büchner, T ;
Berdel, WE ;
Schoch, C ;
Haferlach, T ;
Serve, HL ;
Kienast, J ;
Schnittger, S ;
Kern, W ;
Tchinda, J ;
Reichle, A ;
Lengfelder, E ;
Staib, P ;
Ludwig, WD ;
Aul, C ;
Eimermacher, H ;
Balleisen, L ;
Sauerland, MC ;
Heinecke, A ;
Wöermann, B ;
Hiddemann, W .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2480-2489
[5]   Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].
Cassileth, PA ;
Harrington, DP ;
Appelbaum, FR ;
Lazarus, HM ;
Rowe, JM ;
Paietta, E ;
Willman, C ;
Hurd, DD ;
Bennett, JM ;
Blume, KG ;
Head, DR ;
Wiernik, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656
[6]   Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders [J].
Chang, ChunKang ;
Storer, Barry E. ;
Scott, Bart L. ;
Bryant, Eileen M. ;
Shulman, Howard M. ;
Flowers, Mary E. ;
Sandmaier, Brenda M. ;
Witherspoon, Robert P. ;
Nash, Richard A. ;
Sanders, Jean E. ;
Bedalov, Antonio ;
Hansen, John A. ;
Clurman, Bruce E. ;
Storb, Rainer ;
Appelbaum, Frederick R. ;
Deeg, H. Joachim .
BLOOD, 2007, 110 (04) :1379-1387
[7]   Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? [J].
Cornelissen, Jan J. ;
van Putten, Wim L. J. ;
Verdonck, Leo F. ;
Theobald, Matthias ;
Jacky, Emanuel ;
Daenen, Simon M. G. ;
Kooy, Marinus van Marwijk ;
Wijermans, Pierre ;
Schouten, Harry ;
Huijgens, Peter C. ;
van der Lelie, Hans ;
Fey, Martin ;
Ferrant, Augustin ;
Maertens, Johan ;
Gratwohl, Alois ;
Lowenberg, Bob .
BLOOD, 2007, 109 (09) :3658-3666
[8]   Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML [J].
Craddock, C. F. .
BONE MARROW TRANSPLANTATION, 2008, 41 (05) :415-423
[9]  
de Souza CA, 2005, HAEMATOLOGICA, V90, P232
[10]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956